IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims against Immunomedics Inc. and Advises Investors with Losses to Contact the Firm

LOS ANGELES--()--Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Immunomedics Inc. (“Immunomedics” or the “Company”) (Nasdaq: IMMU). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.

If you purchased or otherwise acquired Immunomedics shares and would like more information regarding the investigation, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.

The investigation concerns whether the Company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Specifically, the investigation will focus on a June 2, 2016, media report that the American Society of Clinical Oncology ("ASCO") had removed a scheduled presentation by Immunomedics regarding the Company's IMMU-132 breast cancer drug from ASCO's annual meeting.

If you have any questions concerning your legal rights in this case, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at info@goldberglawpc.com.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.